Boosting Innate Immunity Through HIF to Treat Drug-Resistant Bacterial Infections

通过 HIF 增强先天免疫来治疗耐药细菌感染

• 批准号: 8116223
• 负责人: RANDALL Scott JOHNSON
• 金额: $ 70.39万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-02 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8116223
• 关键词: Abscess; Address; Agonist; Alleles; Anemia; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Apoptosis; Apoptotic; Ascaridil; Bacteria; Bacterial Infections; Biological Products; Biology; Blood; Cell Death; Cells; Cellular biology; Chromatin; Chronic; Clinical Trials; Collaborations; Communicable Diseases; Companions; Cutaneous; Cytoplasmic Granules; Data; Development; Development Plans; Discipline; Disease; Drug Delivery Systems; Drug Design; Drug Kinetics; Drug resistance; Elements; Epithelial; Epithelium; Family; Food; Gene Expression Regulation; Gene Targeting; Generations; Genes; Genetic; Goals; Gold; Healed; Homeostasis; Host Defense; Human; Hypoxia; Immune; Immune response; Immunogenetics; Immunology; In Vitro; Industry; Infection; Infectious Skin Diseases; Inflammatory; Investigational New Drug Application; Iron; Joints; Journals; Knockout Mice; Knowledge; Laboratories; Laboratory Study; Lead; Leukocytes; Lipopolysaccharides; Lung; Mammalian Genetics; Manuscripts; Mediating; Medicine; Metabolism; Microbiology; Modeling; Molecular; Molecular Immunology; Mus; Myelogenous; Myeloid Cells; NIH Program Announcements; Natural Immunity; Nature; Necrosis; Nitric Oxide; Pathway interactions; Pattern; Peptide Hydrolases; Phagocytes; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physicians; Physiology; Pneumonia; Positioning Attribute; Preclinical Testing; Procollagen-Proline Dioxygenase; Production; Pseudomonas Infections; Pseudomonas aeruginosa; Publications; Publishing; Puncture procedure; Research; Research Personnel; Resistance; Resolution; Role; Safety; Skin; Staphylococcal Infections; Staphylococcus aureus; System; Systemic Therapy; Therapeutic; Tissues; Toll-like receptors; Topical agent; Toxic effect; Toxin; Transcriptional Regulation; Translational Research; Vancomycin; Virulence; Work; Wound Infection; antimicrobial; antimicrobial peptide; bacterial resistance; bactericide; cytokine; drug resistant bacteria; extracellular; healing; hypoxia inducible factor 1; in vivo; in vivo Model; inhibitor/antagonist; innate immune function; innovation; keratinocyte; killings; macrophage; mast cell; methicillin resistant Staphylococcus aureus; microbial; microbicide; mouse model; neutrophil; novel; novel therapeutic intervention; novel therapeutics; overexpression; pathogen; pre-clinical; promoter; response; small molecule; subcutaneous; superinfection; synergism; tool; transcription factor; treatment strategy; treatment trial; wound; Abscess; Address; Agonist; Alleles; Anemia; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Apoptosis; Apoptotic; Ascaridil; Bacteria; Bacterial Infections; Biological Products; Biology; Blood; Cell Death; Cells; Cellular biology; Chromatin; Chronic; Clinical Trials; Collaborations; Communicable Diseases; Companions; Cutaneous; Cytoplasmic Granules; Data; Development; Development Plans; Discipline; Disease; Drug Delivery Systems; Drug Design; Drug Kinetics; Drug resistance; Elements; Epithelial; Epithelium; Family; Food; Gene Expression Regulation; Gene Targeting; Generations; Genes; Genetic; Goals; Gold; Healed; Homeostasis; Host Defense; Human; Hypoxia; Immune; Immune response; Immunogenetics; Immunology; In Vitro; Industry; Infection; Infectious Skin Diseases; Inflammatory; Investigational New Drug Application; Iron; Joints; Journals; Knockout Mice; Knowledge; Laboratories; Laboratory Study; Lead; Leukocytes; Lipopolysaccharides; Lung; Mammalian Genetics; Manuscripts; Mediating; Medicine; Metabolism; Microbiology; Modeling; Molecular; Molecular Immunology; Mus; Myelogenous; Myeloid Cells; NIH Program Announcements; Natural Immunity; Nature; Necrosis; Nitric Oxide; Pathway interactions; Pattern; Peptide Hydrolases; Phagocytes; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physicians; Physiology; Pneumonia; Positioning Attribute; Preclinical Testing; Procollagen-Proline Dioxygenase; Production; Pseudomonas Infections; Pseudomonas aeruginosa; Publications; Publishing; Puncture procedure; Research; Research Personnel; Resistance; Resolution; Role; Safety; Skin; Staphylococcal Infections; Staphylococcus aureus; System; Systemic Therapy; Therapeutic; Tissues; Toll-like receptors; Topical agent; Toxic effect; Toxin; Transcriptional Regulation; Translational Research; Vancomycin; Virulence; Work; Wound Infection; antimicrobial; antimicrobial peptide; bacterial resistance; bactericide; cytokine; drug resistant bacteria; extracellular; healing; hypoxia inducible factor 1; in vivo; in vivo Model; inhibitor/antagonist; innate immune function; innovation; keratinocyte; killings; macrophage; mast cell; methicillin resistant Staphylococcus aureus; microbial; microbicide; mouse model; neutrophil; novel; novel therapeutic intervention; novel therapeutics; overexpression; pathogen; pre-clinical; promoter; response; small molecule; subcutaneous; superinfection; synergism; tool; transcription factor; treatment strategy; treatment trial; wound

暂无数据